Registered Zambia · ZAMRA

Pyrotropy Injection

Gycopyrrolate USP 0.2mg/ml

What it does

Glycopyrrolate is a medication that reduces secretions in the body, such as saliva and sweat. It is often used to help manage certain medical conditions.

Commonly used for: excessive sweating (hyperhidrosis), muscle spasms (muscle spasticity), pre-operative preparation to reduce saliva

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
196/030
Registration date
2021-07-16
Expiry date
2026-07-15
Status
Registered/Compliant
Active ingredient
Gycopyrrolate USP 0.2mg/ml
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Troikaa Pharmaceuticals
Applicant / LTR
Troikaa Pharmaceuticals Ltd
Country of origin
India
Manufacturer location
Troikaa House, Satya Marg, Bodakdev, Ahmedabad, Gujarat 380054, India

Source: Zambia Medicines Regulatory Authority · fetched 2026-03-11 23:59:35 · updated 2026-07-13 04:24:48

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

About this medicine

Glycopyrrolate is a medication that reduces secretions in the body, such as saliva and sweat. It is often used to help manage certain medical conditions.

What it treats

  • excessive sweating (hyperhidrosis)
  • muscle spasms (muscle spasticity)
  • pre-operative preparation to reduce saliva

How it works

Glycopyrrolate works by blocking certain nerve signals that cause the body to produce too much fluid.

Who it's for

This medication is suitable for adults and children who need help managing excessive secretions or muscle spasms.

Cautions

  • • May not be suitable for individuals with certain medical conditions, such as glaucoma or urinary retention.
  • • Use with caution in elderly patients or those with heart problems.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: gycopyrrolate

Glycopyrrolate is an anticholinergic medication primarily used to reduce salivation and secretions in surgical settings, as well as to manage peptic ulcers and certain gastrointestinal disorders. It acts by blocking the action of acetylcholine on muscarinic receptors, leading to decreased glandular secretions and relaxation of smooth muscles.

Indications

  • Reduction of salivation and secretions during surgery
  • Management of peptic ulcers
  • Treatment of gastrointestinal disorders, including irritable bowel syndrome
  • As an adjunct to anesthesia to prevent bradycardia
  • Management of chronic obstructive pulmonary disease (COPD) as a bronchodilator

Dosage

Children: Refer to BNF for Children for specific dosing guidance.

Adults: Refer to BNF for specific dosing guidance.

Mechanism of action

Glycopyrrolate selectively inhibits the action of acetylcholine at muscarinic receptors in the peripheral nervous system. This blockade results in decreased secretions from salivary and sweat glands, as well as a reduction in gastrointestinal motility.

Pharmacodynamics

The drug exhibits dose-dependent effects on the muscarinic receptors, leading to reduced saliva production, decreased gastric acid secretion, and increased heart rate due to its vagolytic properties. Its onset of action is typically within 30 minutes when administered parenterally, with peak effects occurring within 1 hour. The duration of action can last for several hours, depending on the route of administration.

Pharmacokinetics

Glycopyrrolate is well absorbed following parenteral administration, with a bioavailability that can vary based on the route. It is extensively distributed throughout the body, including the central nervous system, although it has limited penetration due to its quaternary ammonium structure. Glycopyrrolate undergoes hepatic metabolism and is excreted primarily in the urine as unchanged drug and metabolites. The half-life ranges from 1 to 2 hours, but this can be prolonged in patients with renal impairment.

Contra-indications

  • Hypersensitivity to glycopyrrolate or any of its components
  • Angle-closure glaucoma
  • Myasthenia gravis
  • Severe ulcerative colitis
  • Tachycardia
  • Obstructive uropathy

Adverse effects

  • Dry mouth
  • Constipation
  • Urinary retention
  • Blurred vision
  • Dizziness
  • Tachycardia
  • Nausea
  • Vomiting
  • Headache

Interactions

  • Anticholinergic agents
  • Antihistamines
  • Tricyclic antidepressants
  • Muscle relaxants
  • Potassium channel blockers

Precautions

  • Use with caution in patients with cardiovascular disease
  • Monitor for signs of urinary retention
  • Caution in elderly patients due to increased risk of adverse effects
  • Be cautious in patients with gastrointestinal obstructions

Pregnancy

Glycopyrrolate is classified as a category C drug. Risk cannot be ruled out; use only if clearly needed.

Breast-feeding

It is unknown if glycopyrrolate is excreted in human milk; caution is advised.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

  • Oral tablets
  • Injection solution

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.